Q-omics provides the consensus-scored MTND4P16 profile across patient tissues and cancer cell-line models. MTND4P16 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MTND4P16 is differentially expressed in 3, with the highest sampling consensus in UCEC. Additionally, MTND4P16 RNA expression shows 6,445 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight THCA, UCEC, and PDAC as cancer lineages where MTND4P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND4P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND4P16 survival associations across molecular data types. MTND4P16 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND4P16 RNA expression–survival associations across cancer types. High MTND4P16 expression shows unfavorable associations in THCA, UCS, READ and LIHC, but favorable associations in KIRP and OV. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MTND4P16 RNA expression.
This table summarizes MTND4P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTND4P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND4P16 shows lower tumor expression in UCEC and BRCA and higher tumor expression in STAD. The UCEC box plot shows higher MTND4P16 RNA expression in normal versus tumor tissue (log2 FC = −0.040, t-test p = .044).
This table shows molecular features associated with MTND4P16 in patient tissues and cancer cell lines. In patient samples, MTND4P16 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
